Mawi iSWAB Microbiome-EL Enables Prime Discoveries’ Development of Rapid Extraction-Less COVID Diagnostic Assay
25.4.2022 16:00:00 EEST | Business Wire | Press release
Mawi DNA Technologies (Mawi), a biotechnology company focusing on the development of innovative technologies for biosampling, announces that Prime Discoveries has successfully developed CovidDetect™, a rapid isothermal amplification diagnostic assay for detecting SARS-CoV-2. Without the need for RNA extraction and purification, the sample result occurs in less than 30 minutes. The assay uses Mawi’s new iSWAB Microbiome-EL (Extraction-Less) sample collection technology. This allows RNA release from the sample and maintains stability, protecting it from degradation and allowing room temperature storage and transport.
Prime Discoveries recently received CE IVD marking for CovidDetect™ and plans to pursue FDA 510K approval soon. Clinical results from Prime CovidDetect™ has been peer reviewed and recently published in PLOS ONE under “A Rapid, Specific, Extraction-Less, and Cost-Effective RT-LAMP Test for the Detection of SARS-CoV-2 in Clinical Specimens.” The CE marking allows deployment of a solution to countries in Africa and Asia where rapid, inexpensive diagnostics for various infections with minimal technical expertise and equipment infrastructure is highly required.
Prime CovidDetect™ leverages Mawi’s unique iSWAB Microbiome-EL sample collection buffer with Prime Discoveries’ patented Loop AMPlification (LAMP) technology. This allows isothermal nucleic acid amplification removing the need for expensive thermal cycling equipment required for PCR. The Extraction-Less protocol bypasses the expensive and complex nucleic acid extraction and purification step, saving 60-90 minutes of sample processing time needed for PCR.
Arun Manoharan, Ph.D., Chief Science Officer at Prime Discoveries, said, “The COVID pandemic has shown that there is a big need for rapid diagnostic assays. Prime Discoveries aims to build a portfolio of solutions which can provide results in under 45 minutes with minimal laboratory, reagent and technical skill requirements. This is ideal for point of care testing in rural neighborhoods, mobile testing, border points of entry and clinical locations with minimal infrastructure. Our work with COVID has shown stable performance of the Mawi iSWAB Microbiome-EL for hundreds of clinical samples with similar or superior performance to RT-PCR solutions. Samples have been stable for more than two weeks with minimal RNA degradation along with high compatibility with our isothermal nucleic acid amplification techniques.” He added, “Our partnership with Mawi enables Prime Discoveries to develop room temperature sampling with Extraction-Less capabilities for our rapid diagnostic solutions in many areas. These include influenza, chlamydia, gonorrhea, trichomonas, HBV, HCV, HPV, TB, herpes, syphilis, etc. We are excited to partner with Mawi for future products empowering customers to test thousands of patients rapidly for various infections including respiratory, gastrointestinal, sexually transmitted pathogens and those with anti-microbial resistance.”
About Prime Discoveries
Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Founded in NYC in 2017, Prime’s scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and New York University. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar (Bloomberg), Esther Dyson (23 & Me), BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others. For more information, visit www.primediscoveries.com.
About Mawi DNA Technologies
Mawi DNA Technologies, founded in 2013, has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Mawi’s mission is to uphold sample integrity from anywhere in the world at room temperature, enabling true sample diversity across any geography or population segment. At Mawi, The Future of Biosampling is Here™. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005323/en/
Contact information
Investors:
Jerome David, VP of Sales and Marketing
510-256-5186, j.david@mawidna.com
Media Contact:
Susan Tellem, APR, RN, BSN
310-313-3444, susan@tellemgrodypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE Opens 15 th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million26.9.2026 23:51:00 EEST | Press release
The 15th United Nations Congress on Crime Prevention and Criminal Justice – Abu Dhabi 2026 kicked off today at ADNEC Centre Abu Dhabi. Set to run until 1 October, the Congress attracts representatives from over 97 countries, including over 32 ministers of justice and interior ministers, alongside senior officials, judges, prosecutors, experts, and youth from around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260926005703/en/ UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million (Photo: AETOSWire) The opening session witnessed the adoption of the Abu Dhabi Declaration, which serves as the Congress's principal political and strategic outcome document and will guide international priorities and cooperation in crime prevention, criminal justice and the rule of law over the next five years. The Declaration is structured around four pi
Future Health Convenes Global Health Leaders at UNGA to Advance Health System Transformation at Scale26.9.2026 18:21:00 EEST | Press release
Future Health – A Global Initiative by Abu Dhabi convened Ministers, senior government representatives, and global health leaders in New York on the sidelines of the 81st Session of the United Nations General Assembly (UNGA 81). The high-level dialogue set out practical priorities for moving health systems from reactive treatment towards prediction, prevention, and earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260926746202/en/ Future Health – A Global Initiative by Abu Dhabi convened Ministers, senior government representatives, and global health leaders in New York on the sidelines of the 81st Session of the United Nations General Assembly (UNGA 81). Chaired by H.E. Ahmed Al Sayegh, Minister of Health and Prevention of the United Arab Emirates, the dialogue brought together participants from Angola, Brazil, Ethiopia, Finland, Guyana, Indonesia, Madagascar, Mali, Nigeria, Rwanda, Sweden, the United Ara
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom